• Tech
• Gadgets
• Mobile
• Enterprise
• CrunchBase
• More
  • Beta Invites
  • Elevator Pitches
  • Gillmor Gang
  • Podcasts
  • TechCrunch50
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Sirtris Pharmaceuticals

edit

Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.

via: Sirtris

Milestones

edit

• Acquired by GlaxoSmithKline for $720M. (4/22/08)
  Posted 5/21/08 at 2:03pm
• Received $37M in Series C funding. (4/19/06)
  Posted 5/21/08 at 2:11pm
• Received $27M in Series B funding. (3/8/05)
  Posted 5/21/08 at 2:09pm
• Received $13M in Series A funding. (12/1/04)
  Posted 5/21/08 at 2:09pm
• Received $5M in Seed funding.
  Posted 5/21/08 at 2:09pm

Videos

Screenshots

edit

Traffic Analytics

Quantcast

Compete

Sources

1. GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development (phx.corporate-ir.net) [edit]
2. Citation Needed [add]
3. Sirtris closes $13 million financing (boston.bizjournals.com) [edit]
4. Sirtris Pharmaceuticals closes $27M second round (boston.bizjournals.com) [edit]
5. Sirtris pockets $37M in venture funds (fiercebiotech.com) [edit]